RecruitingPhase 2NCT07800572

Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL-2)

Efficacy and Safety of Anisodine Hydrobromide in Patients With Ischemic Stroke Undergoing Endovascular Treatment

Sponsor

Capital Medical University

Enrollment

204 participants

Start Date

Sep 6, 2026

Study Type

INTERVENTIONAL

Conditions

Acute Ischemic Stroke

Summary

This phase 2, multicenter, randomized, double-blind, placebo-controlled trial will evaluate the efficacy and safety of anisodine hydrobromide in patients with acute ischemic stroke undergoing endovascular thrombectomy.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Anisodine Hydrobromide and a drug called Anisodine Hydrobromide Placebo for people with acute ischemic stroke. The study is currently recruiting participants at 11 locations. People eligible for this study include aged 18 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAnisodine Hydrobromide

Anisodine hydrobromide, 2 mg per dose, diluted in 0.9% sodium chloride solution and administered by intravenous infusion twice daily for a total of 14 doses.

DRUGAnisodine Hydrobromide Placebo

An equivalent volume of 0.9% sodium chloride solution, administered by intravenous infusion twice daily for a total of 14 doses.

Locations(11)

Anyang People's Hospital

Anyang, China

Xuanwu Hospital，Capital Medical University

Beijing, China

Anji County People's Hospital

Huzhou, China

Jiuquan People's Hospital

Jiuquan, China

Lishui Central Hospital

Lishui, China

Shangqiu First People's Hospitl

Shangqiu, China

Suzhou Municipal Hospital of Anhui Province

Suzhou, China

Taizhou Enze Medical Center (Group) Enze Hospital

Taizhou, China

The Affiliated Hospital of Xuzhou Medical University

Xuzhou, China

Zhangpu County Hospital

Zhangzhou, China

Zibo Central Hospital

Zibo, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07800572

Related Trials

A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well

NCT07361302246 locations

Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

NCT0569124454 locations

Albumin for Patients With Acute Large Vessel Occlusive Stroke Undergoing Endovascular Therapy -2

NCT0726330812 locations

Intravenous rhPro-UK Before Stroke Thrombectomy in the Extended Time Window (BRIDGE-PUK EXTEND)

NCT07389460

Effect of Balloon Angioplasty vs Stenting Following Residual Stenosis After Endovascular Treatment of Intracranial Atherosclerotic Acute Ischemic Stroke

NCT07026331